Michael Davidson, NewAmsterdam Pharma CEO (Caladrius)
May 28, 2024 09:54 AM EDT
R&D

NewAms­ter­dam says for­mer Am­gen car­dio drug re­duces heart dis­ease risk fac­tor

Nicole DeFeudis

Editor

A Dutch biotech has proved its res­ur­rect­ed Am­gen drug is ca­pa­ble of sig­nif­i­cant­ly low­er­ing “bad” cho­les­terol in a hand­ful of mid-stage tri­als in re­cent years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times